How This Evidence Evolved
Status Epilepticus Second-Line Agents
Three drugs, one answer
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Integration into clinical practice guidelines and recommendations
Current standard of care and ongoing research directions
Landmark Trials in This Story
A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group
Verified overt SE: seizure cessation within 20 min, no recurrence for 40 min; lorazepam 64.9% vs phenytoin 43.6%
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
No clinical seizures plus improved consciousness by 60 min, without rescue: levetiracetam 47%, fosphenytoin 45%, valproate 46%
Intramuscular versus intravenous therapy for prehospital status epilepticus.
Seizures absent without rescue therapy at emergency department arrival: intramuscular midazolam 73.4% vs intravenous lorazepam 63.4% (absolute difference 10 percentage points, 95% CI 4.0 to 16.1; P<0.001).
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.